What's Happening?
Chip Baird, former head of 2seventy, has launched Poplar Therapeutics, a company focused on developing treatments for food allergies and other atopic conditions. After selling 2seventy to Bristol Myers Squibb in 2025, Baird sought new opportunities in the biotech
sector, ultimately deciding to focus on food allergies. Poplar Therapeutics has raised $95 million, including a $45 million Series A extension, to support its early-stage program for PHB-050, a next-generation anti-IgE antibody. This drug aims to address multiple atopic diseases by blocking IgE from binding to mast cells, thus preventing allergic reactions. The company plans to release data from its Phase 1 trials in the second half of the year.
Why It's Important?
The launch of Poplar Therapeutics represents a significant development in the treatment of food allergies, a condition affecting millions in the U.S. The company's approach could offer a new solution for patients who do not respond well to existing treatments like Xolair, which requires bi-weekly injections and does not eliminate IgE. Poplar's PHB-050 aims to reduce IgE levels to zero, potentially offering a more effective and less frequent treatment option. This could transform the market for allergy treatments, providing relief for patients with severe allergies and expanding options for those with higher IgE levels or body weight who cannot use current therapies.
What's Next?
Poplar Therapeutics is set to release data from its Phase 1 trials later this year, which will be crucial in determining the drug's efficacy and safety. The company will need to differentiate its product from existing treatments to capture market share. As it progresses, Poplar will likely face competition from established players like Genentech and Novartis, but its unique approach could carve out a niche in the allergy treatment market. Success in these trials could lead to further investment and development, potentially expanding the drug's application to other atopic conditions.
